全文获取类型
收费全文 | 3718842篇 |
免费 | 312705篇 |
国内免费 | 14496篇 |
专业分类
耳鼻咽喉 | 50629篇 |
儿科学 | 118656篇 |
妇产科学 | 97617篇 |
基础医学 | 581056篇 |
口腔科学 | 102255篇 |
临床医学 | 335818篇 |
内科学 | 659548篇 |
皮肤病学 | 98462篇 |
神经病学 | 311796篇 |
特种医学 | 146763篇 |
外国民族医学 | 262篇 |
外科学 | 578653篇 |
综合类 | 113554篇 |
现状与发展 | 23篇 |
一般理论 | 2354篇 |
预防医学 | 303506篇 |
眼科学 | 88517篇 |
药学 | 259830篇 |
21篇 | |
中国医学 | 11028篇 |
肿瘤学 | 185695篇 |
出版年
2021年 | 50002篇 |
2020年 | 35502篇 |
2019年 | 58641篇 |
2018年 | 72879篇 |
2017年 | 55295篇 |
2016年 | 61195篇 |
2015年 | 74927篇 |
2014年 | 109236篇 |
2013年 | 174716篇 |
2012年 | 104785篇 |
2011年 | 106665篇 |
2010年 | 120969篇 |
2009年 | 123878篇 |
2008年 | 93229篇 |
2007年 | 97803篇 |
2006年 | 107322篇 |
2005年 | 102113篇 |
2004年 | 103805篇 |
2003年 | 93329篇 |
2002年 | 82587篇 |
2001年 | 135673篇 |
2000年 | 128823篇 |
1999年 | 119866篇 |
1998年 | 62905篇 |
1997年 | 59505篇 |
1996年 | 57139篇 |
1995年 | 58034篇 |
1994年 | 52133篇 |
1993年 | 48494篇 |
1992年 | 84898篇 |
1991年 | 81109篇 |
1990年 | 76723篇 |
1989年 | 75134篇 |
1988年 | 68929篇 |
1987年 | 67173篇 |
1986年 | 63501篇 |
1985年 | 62738篇 |
1984年 | 54638篇 |
1983年 | 49239篇 |
1982年 | 43196篇 |
1981年 | 40562篇 |
1980年 | 38007篇 |
1979年 | 44555篇 |
1978年 | 37949篇 |
1977年 | 34520篇 |
1976年 | 31615篇 |
1975年 | 30505篇 |
1974年 | 32294篇 |
1973年 | 31025篇 |
1972年 | 28981篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
81.
Boothe Emily Olenderek Marta Noyola M. Cristina Rushing Julia Allred Erinn Kaplan Sebastian 《Zeitschrift fur Gesundheitswissenschaften》2022,30(6):1373-1380
Journal of Public Health - Group prenatal care provides an alternative model of prenatal care that allows for collaboration with peers, education, discussion, and self-management training in... 相似文献
82.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献
83.
Peng L. Q. Wu X. X. Chen G. Cai H. Z. Tang Y. P. Chen Q. Y. Chen X. Y. 《Bulletin of experimental biology and medicine》2022,173(3):335-340
Bulletin of Experimental Biology and Medicine - This study aimed to explore the effects of Wenyang Zhenshuai granules (WZG) on the morphology of cardiomyocytes, cell viability, and the expression... 相似文献
84.
85.
- DNA is the sequence that codes for proteins.
- Messenger RNA is transcribed from the DNA sequence of genes and translated into protein.
- It can be difficult to predict how a change in the DNA sequence will affect messenger RNA and protein quantity and quality.
- DNA translocation changes can cause the joining of sequences from two different genes or different parts of the same gene.
- DNA sequencing is often used clinically to predict how DNA changes might affect proteins.
- Alternatively, RNA sequencing can be used as a more direct measure of the effect of DNA changes on the protein products.
- This sequencing is important for identifying changes in cancer that may indicate response to targeted therapy, prognosis, or diagnosis.
86.
Sigve Nakken Sveinung Gundersen Fabian L. M. Bernal Dimitris Polychronopoulos Eivind Hovig Jørgen Wesche 《International journal of cancer. Journal international du cancer》2023,153(10):1819-1828
Genome-scale screening experiments in cancer produce long lists of candidate genes that require extensive interpretation for biological insight and prioritization for follow-up studies. Interrogation of gene lists frequently represents a significant and time-consuming undertaking, in which experimental biologists typically combine results from a variety of bioinformatics resources in an attempt to portray and understand cancer relevance. As a means to simplify and strengthen the support for this endeavor, we have developed oncoEnrichR, a flexible bioinformatics tool that allows cancer researchers to comprehensively interrogate a given gene list along multiple facets of cancer relevance. oncoEnrichR differs from general gene set analysis frameworks through the integration of an extensive set of prior knowledge specifically relevant for cancer, including ranked gene-tumor type associations, literature-supported proto-oncogene and tumor suppressor gene annotations, target druggability data, regulatory interactions, synthetic lethality predictions, as well as prognostic associations, gene aberrations and co-expression patterns across tumor types. The software produces a structured and user-friendly analysis report as its main output, where versions of all underlying data resources are explicitly logged, the latter being a critical component for reproducible science. We demonstrate the usefulness of oncoEnrichR through interrogation of two candidate lists from proteomic and CRISPR screens. oncoEnrichR is freely available as a web-based service hosted by the Galaxy platform ( https://oncotools.elixir.no ), and can also be accessed as a stand-alone R package ( https://github.com/sigven/oncoEnrichR ). 相似文献
87.
88.
89.
Marie V. Plaisime PhD MPH Marie Jipguep-Akhtar PhD Joseph J. Locascio PhD Harolyn M. E. Belcher MD MHS Rachel R. Hardeman PhD MPH Katherine Picho-Kiroga PhD Sylvia P. Perry PhD Sean M. Phelan PhD MPH Michelle van Ryn PhD LMFT MPH John F. Dovidio PhD 《Health services research》2023,58(Z2):229-237